Dedifferentiated Liposarcoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: DDF001 MIFTS: 47	Dedifferentiated Liposarcoma Categories: Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Dedifferentiated Liposarcoma

MalaCards integrated aliases for Dedifferentiated Liposarcoma:

Name: Dedifferentiated Liposarcoma ⁵⁹

Liposarcoma, Dedifferentiated ⁷³

Liposarcoma Dedifferentiated ⁵⁵

Ddls ⁵⁹

Characteristics:

Orphanet epidemiological data:

⁵⁹

dedifferentiated liposarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult; Age of death: adult;

Classifications:

MalaCards categories:
Global: Rare diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Neoplasms

Malignant neoplasms of mesothelial and soft tissue

Malignant neoplasm of other connective and soft tissue

Malignant neoplasm: Connective and soft tissue, unspecified

External Ids:

Orphanet ⁵⁹ ORPHA99970

UMLS via Orphanet ⁷⁴ C0205824

ICD10 via Orphanet ³⁴ C49.9

UMLS ⁷³ C0205824

Sources

Summaries for Dedifferentiated Liposarcoma

MalaCards based summary : Dedifferentiated Liposarcoma, also known as liposarcoma, dedifferentiated, is related to histiocytoma and hemangiopericytoma, malignant. An important gene associated with Dedifferentiated Liposarcoma is MDM2 (MDM2 Proto-Oncogene), and among its related pathways/superpathways are ERK Signaling and Cell Cycle, Mitotic. The drugs Rosiglitazone and Mechlorethamine have been mentioned in the context of this disorder. Affiliated tissues include bone, colon and testes, and related phenotypes are Decreased CDKN1A mRNA expression and Decreased CDKN1A mRNA expression

Sources

Related Diseases for Dedifferentiated Liposarcoma

Diseases related to Dedifferentiated Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 242)

#	Related Disease	Score	Top Affiliating Genes
1	histiocytoma	30.6	CDK4 MDM2 TP53
2	hemangiopericytoma, malignant	29.5	ACTC1 DES MDM2 MUC1
3	inflammatory myofibroblastic tumor	29.4	ACTC1 DES MDM2 TP53
4	atypical lipomatous tumor	29.1	CDK4 CDKN2A HMGA2 MDM2
5	leiomyosarcoma	29.0	ACTC1 CDK4 DES MDM2 TP53
6	malignant fibroxanthoma	29.0	ACTC1 CDK4 DES MDM2 MUC1
7	liposarcoma	29.0	CDK4 CDKN2A DES HMGA2 MDM2 TP53
8	rhabdomyosarcoma	28.8	ACTC1 CDK4 DES MDM2 TP53
9	myxoid liposarcoma	28.6	CDK4 HMGA2 MDM2 TP53
10	pleomorphic liposarcoma	28.5	ACTC1 CDKN2A DES MDM2 MUC1
11	well-differentiated liposarcoma	28.3	CDK4 CDKN2A HMGA2 MDM2 MUC1
12	malignant peripheral nerve sheath tumor	27.4	ACTC1 CDK4 CDKN2A MDM2 MUC1 TP53
13	undifferentiated embryonal sarcoma of the liver	10.8	CDK4 MDM2
14	extraosseous osteosarcoma	10.8	CDK4 MDM2
15	inflammatory mfh	10.8	CDK4 MDM2
16	bone osteosarcoma	10.8	CDK4 MDM2
17	lipoblastoma	10.8	CDK4 MDM2
18	mixed liposarcoma	10.7	CDK4 MDM2
19	spindle cell liposarcoma	10.7	CDK4 MDM2
20	chondroid lipoma	10.7	CDK4 MDM2
21	juxtacortical osteosarcoma	10.7	CDK4 MDM2
22	ovarian fibrothecoma	10.6	ACTC1 DES
23	fibroblastic rheumatism	10.6	ACTC1 DES
24	angiolipoma	10.6	ACTC1 DES
25	zika virus infection	10.6	MDM2 TP53
26	botryoid rhabdomyosarcoma	10.6	ACTC1 DES
27	epithelioid leiomyosarcoma	10.6	ACTC1 DES
28	actinic cheilitis	10.6	MDM2 TP53
29	benign metastasizing leiomyoma	10.6	ACTC1 DES
30	sclerosing liposarcoma	10.6	MDM2 TP53
31	lip cancer	10.6	MDM2 TP53
32	congenital fibrosarcoma	10.5	ACTC1 DES
33	pulmonary vein stenosis	10.5	ACTC1 DES
34	bizarre leiomyoma	10.5	ACTC1 CDKN2A
35	cystic nephroma	10.5	ACTC1 DES
36	peripheral osteosarcoma	10.5	CDK4 MDM2
37	cutaneous fibrous histiocytoma	10.5	ACTC1 DES
38	brain stem astrocytic neoplasm	10.5	CDKN2A TP53
39	bilateral retinoblastoma	10.5	DES RB1
40	non-langerhans-cell histiocytosis	10.5	ACTC1 DES
41	gliomatosis cerebri	10.5	MDM2 TP53
42	pseudosarcomatous fibromatosis	10.5	ACTC1 DES
43	soft tissue sarcoma	10.5	MDM2 TP53
44	keratinizing squamous cell carcinoma	10.5	CDKN2A TP53
45	gallbladder adenoma	10.5	CDKN2A RB1
46	spitz nevus	10.5	CDKN2A TP53
47	bladder carcinoma in situ	10.4	CDKN2A TP53
48	bartholin's gland benign neoplasm	10.4	CDKN2A TP53
49	vulva squamous cell carcinoma	10.4	CDKN2A TP53
50	thyroid lymphoma	10.4	CDKN2A TP53

Graphical network of the top 20 diseases related to Dedifferentiated Liposarcoma:

Sources

Symptoms & Phenotypes for Dedifferentiated Liposarcoma

GenomeRNAi Phenotypes related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased CDKN1A mRNA expression	GR00389-S-1	9.13	TP53
2	Decreased CDKN1A mRNA expression	GR00389-S-2	9.13	HMGA2 TP53
3	Increased TP53 mRNA expression	GR00389-S-6	8.62	HMGA2 TP53

MGI Mouse Phenotypes related to Dedifferentiated Liposarcoma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	9.95	ACTC1 CDK4 CDKN2A DES MDM2 RB1
2	cellular	MP:0005384	9.91	ACTC1 CDK4 CDKN2A DES MDM2 RB1
3	digestive/alimentary	MP:0005381	9.72	CDK4 CDKN2A MDM2 RB1 TP53
4	muscle	MP:0005369	9.7	MDM2 RB1 TP53 ACTC1 CDK4 CDKN2A
5	liver/biliary system	MP:0005370	9.65	CDKN2A MDM2 RB1 TP53 CDK4
6	neoplasm	MP:0002006	9.35	CDK4 CDKN2A MDM2 RB1 TP53
7	pigmentation	MP:0001186	9.02	CDK4 CDKN2A MDM2 RB1 TP53

Sources

Drugs & Therapeutics for Dedifferentiated Liposarcoma

Drugs for Dedifferentiated Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 23)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Rosiglitazone

Approved, Investigational

Phase 2

122320-73-4

77999

Mechlorethamine

Approved, Investigational

Phase 2

51-75-2

4033

Ifosfamide

Approved

Phase 2

3778-73-2

3690

Mesna

Approved, Investigational

Phase 2

3375-50-6

598

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Everolimus

Approved

Phase 2

159351-69-6

6442177

Pembrolizumab

Approved

Phase 2

1374853-91-4

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030 46835353

nivolumab

Approved

Phase 2

946414-94-4

Trabectedin

Approved, Investigational

Phase 2

114899-77-3

108150

Maleic acid

Experimental

Phase 2

110-16-7

444266

Hypoglycemic Agents

Phase 2

Isophosphamide mustard

Phase 2

Alkylating Agents

Phase 2

Anti-Bacterial Agents

Phase 2

Antibiotics, Antitubercular

Phase 2

Antibodies

Phase 2

Immunoglobulins

Phase 2

Antibodies, Monoclonal

Phase 2

Immunosuppressive Agents

Phase 2

Anti-Infective Agents

Phase 2

Antifungal Agents

Phase 2

Antineoplastic Agents, Alkylating

Phase 2

Interventional clinical trials:

(show all 16)

#	Name	Status	NCT ID	Phase	Drugs
1	Selinexor in Advanced Liposarcoma	Recruiting	NCT02606461	Phase 2, Phase 3	Selinexor;Placebo
2	Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial	Unknown status	NCT01692496	Phase 2	Pazopanib
3	Rosiglitazone in Treating Patients With Liposarcoma	Completed	NCT00004180	Phase 2	rosiglitazone maleate
4	Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)	Recruiting	NCT03114527	Phase 2	Ribociclib;Everolimus
5	Study of Abemaciclib in Dedifferentiated Liposarcoma	Recruiting	NCT02846987	Phase 2	Abemaciclib
6	Ph II Cabazitaxel DD Liposarcoma	Recruiting	NCT01913652	Phase 2	Cabazitaxel
7	A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma	Recruiting	NCT03096912	Phase 2	Ribociclib
8	Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma	Recruiting	NCT02247544	Phase 2	Trabectedin
9	Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma	Recruiting	NCT03307616	Phase 2	Nivolumab;Ipilimumab
10	SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas	Recruiting	NCT02301039	Phase 2	Pembrolizumab
11	Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery	Recruiting	NCT02500797	Phase 2
12	A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma	Active, not recruiting	NCT02571829	Phase 2	ribociclib
13	Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial	Terminated	NCT01876043	Phase 2	plitidepsin
14	Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma	Withdrawn	NCT00969917	Phase 2	IPI-504
15	Phase 1 Safety Testing of SAR405838	Completed	NCT01636479	Phase 1	SAR405838
16	The FGF/FGFR Signalling Pathway:	Recruiting	NCT03303885

Search NIH Clinical Center for Dedifferentiated Liposarcoma

Sources

Genetic Tests for Dedifferentiated Liposarcoma

Sources

Anatomical Context for Dedifferentiated Liposarcoma

MalaCards organs/tissues related to Dedifferentiated Liposarcoma:

⁴¹

Bone, Colon, Testes, Lung, Liver, Lymph Node, Kidney

Sources

Publications for Dedifferentiated Liposarcoma

Articles related to Dedifferentiated Liposarcoma:

(show top 50) (show all 227)

#	Title	Authors	Year
1	Dedifferentiated Liposarcoma Occurring in the Right Pulmonary Hilum. ( 29491279 )	Koike H....Ashizawa K.	2018
2	Dedifferentiated Liposarcoma With Rhabdomyosarcomatous Differentiation Producing HCG: A Case Report of a Diagnostic Pitfall. ( 29532681 )	Maryamchik E....Rosenberg A.E.	2018
3	Amplification of FRS2 in atypical lipomatous tumour/well -differentiated liposarcoma and dedifferentiated liposarcoma: a clinicopathological and genetic study of 146 cases. ( 29368794 )	Jing W....Zhang H.	2018
4	Dedifferentiated liposarcoma of the oral floor: A case study and literature review of 50 cases of head and neck neoplasm. ( 29740489 )	Nimura F....Nishihara K.	2018
5	Whole blood miRNA expression analysis reveals miR-3613-3p as a potential biomarker for dedifferentiated liposarcoma. ( 29689704 )	Fricke A....Eisenhardt S.U.	2018
6	Giant Primary Retroperitoneal Dedifferentiated Liposarcoma. ( 29959642 )	Carboni F....Garofalo A.	2018
7	Second Primary Malignancies in Patients with Well-differentiated/Dedifferentiated Liposarcoma. ( 29848707 )	Jung E....Tseng W.W.	2018
8	Clarifying the Distinction Between Malignant Peripheral Nerve Sheath Tumor and Dedifferentiated Liposarcoma: A Critical Reappraisal of the Diagnostic Utility of MDM2 and H3K27me3 Status. ( 29309298 )	Makise N....Yoshida A.	2018
9	A dedifferentiated liposarcoma with inflammatory myofibroblastic tumor-like features. ( 29446522 )	Kai K....Aishima S.	2018
10	Primary Breast Atypical Lipomatous Tumor/ Well-Differentiated Liposarcoma and Dedifferentiated Liposarcoma. ( 29372852 )	Briski L.M....Jorns J.M.	2018
11	Dedifferentiated liposarcoma composed predominantly of rhabdoid/epithelioid cells: a frequently misdiagnosed highly aggressive variant. ( 29307627 )	Agaimy A....Michal M.	2018
12	Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. ( 29731991 )	Somaiah N....Hong D.	2018
13	Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin. ( 29610390 )	Beird H.C....Somaiah N.	2018
14	Recurrent paratesticular dedifferentiated liposarcoma after contralateral radical orchiectomy. ( 29623907 )	Wang J....Wang C.X.	2018
15	Giant retroperitoneal dedifferentiated liposarcoma. ( 28098568 )	Beksac K....Kandemir O.	2017
16	Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. ( 28928422 )	Livingston J.A....Somaiah N.	2017
17	A retroperitoneal dedifferentiated liposarcoma mimicking an ovarian tumor. ( 29184870 )	Kim H....Ju M.	2017
18	Retroperitoneal dedifferentiated liposarcoma with huge cystic degeneration: A case report. ( 28337832 )	Uchihashi K....Hisaoka M.	2017
19	Identification of key genes and molecular mechanisms associated with dedifferentiated liposarcoma based on bioinformatic methods. ( 28670134 )	Yu H....Zhu H.	2017
20	Primary colonic well-differentiatedA /A dedifferentiated liposarcoma of the ascending colon: a case report. ( 28856628 )	Sawayama H....Baba H.	2017
21	A rare case of dedifferentiated liposarcoma of the sinonasal cavity: A case report. ( 29046788 )	Miyazaki M....Nabeshima K.	2017
22	Dedifferentiated Liposarcoma of the Retroperitoneum With Heterologous Osteosarcomatous Differentiation and a Striking Aneurysmal Bone Cyst-Like Morphology. ( 28193096 )	Van Haverbeke C....Creytens D.	2017
23	p16 Immunohistochemistry is Less Useful Than MDM2 and CDK4 to Distinguish Dedifferentiated Liposarcomas From Other Retroperitoneal Mimics. ( 26509911 )	Kang Y....Horvai A.E.	2017
24	Systemic Therapy in Metastatic or Unresectable Well-Differentiated/Dedifferentiated Liposarcoma. ( 29250486 )	McGovern Y....Jones R.L.	2017
25	An unusual case of primary colonic dedifferentiated liposarcoma with confusing presentation. ( 29492941 )	Zehani A....Kchir N.	2017
26	Atypical lipomatous tumor of the hand with transformation to dedifferentiated liposarcoma: a case report. ( 29209735 )	Ramirez D.C....Hameed M.	2017
27	Preoperative Radiation Therapy With Simultaneous Integrated Boost Dose Escalation for Optimal Local Control of Retroperitoneal Dedifferentiated Liposarcoma. ( 28463146 )	Petersen I.A.	2017
28	Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma. ( 28099935 )	Asano N....Ichikawa H.	2017
29	Osteogenic differentiation in dedifferentiated liposarcoma: a study of 36 cases in comparison to the cases without ossification. ( 29076540 )	Yamashita K....Toyokuni S.	2017
30	High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: A cytogenomic microarray analysis of 47 cases. ( 29153098 )	Ricciotti R.W....Liu Y.J.	2017
31	Dedifferentiated Liposarcoma With Epithelioid/Epithelial Features. ( 28719466 )	Makise N....Hiraoka N.	2017
32	Malignant solitary fibrous tumour of the kidney with lymph node and liver metastases: beware of STAT6 expression in dedifferentiated liposarcoma with a solitary fibrous tumour-like morphology: author reply. ( 28838615 )	Yang Y....Eyzaguirre E.	2017
33	Comparison between retroperitoneal leiomyosarcoma and dedifferentiated liposarcoma. ( 28552535 )	Ishii T....Oda Y.	2017
34	Mediastinal dedifferentiated liposarcoma. ( 28707566 )	Sbrana F....Pasanisi E.M.	2017
35	A case of dedifferentiated liposarcoma of the heart and stomach. ( 29031176 )	Hisata Y....Yamada T.	2017
36	Malignant solitary fibrous tumour of the kidney with lymph node and liver metastases: beware of STAT6 expression in dedifferentiated liposarcoma with a solitary fibrous tumour-like morphology. ( 28822554 )	Creytens D.	2017
37	Scattered genomic amplification in dedifferentiated liposarcoma. ( 28652867 )	Mandahl N....Mertens F.	2017
38	Dedifferentiated Liposarcoma Mimicking a Primary Colon Mass. ( 28950740 )	Hollowoa B....Gardner J.M.	2017
39	Dedifferentiated Liposarcoma in the Spermatic Cord Finally Diagnosed at 7th Resection of Recurrence: A Case Report and Bibliographic Consideration. ( 28878655 )	Morozumi K....Arai Y.	2017
40	Dedifferentiated liposarcoma of the lower extremity with low-grade dedifferentiation and low-grade osteosarcomatous component. ( 27909788 )	Zajicek A.K....Walker C.W.	2017
41	Multiple Primary Dedifferentiated Liposarcoma of the Jejunal Mesentery: A Case Report and Review of Literature. ( 26894164 )	Vats M....Singh N.	2016
42	Dedifferentiated Liposarcoma of the Esophagus: A Case Report and Selected Review of the Literature. ( 28191296 )	Brett C.L....Miller R.C.	2016
43	MDM2 Expression in Extranodal Abdominal and Retroperitoneal Follicular Dendritic Cell Sarcomas, Mimicking Dedifferentiated Liposarcomas. ( 26180935 )	Creytens D.	2016
44	Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry. ( 27597521 )	Kammerer-Jacquet S.F....Stock N.	2016
45	Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma. ( 27409346 )	Hanes R....Myklebost O.	2016
46	Plasma levels of miRNA-155 as a powerful diagnostic marker for dedifferentiated liposarcoma. ( 27186423 )	Boro A....Fuchs B.	2016
47	Primary mediastinal dedifferentiated liposarcoma resected by lateral thoracotomy with video-assisted thoracoscopic surgery. ( 26724326 )	Hamanaka K....Nakamura T.	2016
48	Rare Aggressive Behavior of MDM2-Amplified Retroperitoneal Dedifferentiated Liposarcoma, with Brain, Lung and Subcutaneous Metastases. ( 27746879 )	Ben Salha I....Thway K.	2016
49	Dedifferentiated Liposarcoma: Updates on Morphology, Genetics, and Therapeutic Strategies. ( 26645460 )	Thway K....Fisher C.	2016
50	Dedifferentiated Liposarcoma of Sigmoid Mesocolon - A Case Report. ( 27604671 )	Constantinoiu S....Mates I.N.	2016

Sources

Genes for Dedifferentiated Liposarcoma

Genes related to Dedifferentiated Liposarcoma (3 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	MDM2	MDM2 Proto-Oncogene	Protein Coding	54.01	Role in the phenotype ⁵⁹ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	15221942 18500263 9071997 (more) 18214854 17638873 19946100 12640106 18204431 17895748 16160477 11518050 19688222 18836421 19737942 19664496 16442827 15242313 16489442 11484509 18820664
2	CDK4	Cyclin Dependent Kinase 4	Protein Coding	53.46	Role in the phenotype ⁵⁹ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	15221942 18214854 19737942 (more) 19946100 12640106 18204431 18820664 16442827 19664496 19454362 16160477 17895748 16489442
3	HMGA2	High Mobility Group AT-Hook 2	Protein Coding	44.1	Role in the phenotype ⁵⁹ Novoseek inferred ⁵⁵ GeneCards inferred via : Novoseek inferred (show sections)	18214854 19737942
4	DES	Desmin	Protein Coding	26.43	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	9331894 11480734 16472759
5	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	17.69	GeneCards inferred via : Publications (show sections)
6	ACTC1	Actin, Alpha, Cardiac Muscle 1	Protein Coding	17.23	GeneCards inferred via : Publications (show sections)
7	TP53	Tumor Protein P53	Protein Coding	17.23	GeneCards inferred via : Publications (show sections)
8	RB1	RB Transcriptional Corepressor 1	Protein Coding	16.93	Novoseek inferred ⁵⁵ GeneCards inferred via : Novoseek inferred (show sections)	12210086 15933756
9	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	16.88	GeneCards inferred via : Publications (show sections)

Sources

Variations for Dedifferentiated Liposarcoma

Sources

Expression for Dedifferentiated Liposarcoma

Search GEO for disease gene expression data for Dedifferentiated Liposarcoma.

Sources

Pathways for Dedifferentiated Liposarcoma

Pathways related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

(show all 49)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.67	CDK4 CDKN2A DES MDM2 MUC1 RB1
2	Cell Cycle, Mitotic ⁶⁶ Show member pathways Cell Cycle ⁶⁶ M Phase ⁶⁶	13.26	CDK4 CDKN2A MDM2 RB1 TP53
3	Cellular Senescence (REACTOME) ⁶⁶ Show member pathways Cellular Senescence ⁶⁶ Oxidative Stress Induced Senescence ⁶⁶ Senescence-Associated Secretory Phenotype (SASP) ⁶⁶	12.97	CDK4 CDKN2A HMGA2 MDM2 RB1 TP53
4	Aldosterone synthesis and secretion ³⁷ Show member pathways Adrenergic signaling in cardiomyocytes ³⁷ Ca2+ activated K+ channels ⁶⁶ Cortisol synthesis and secretion ³⁷ Cushing's syndrome ³⁷ Insulin secretion ³⁷ Melanogenesis ³⁷ Thyroid hormone synthesis ³⁷	12.86	ACTC1 CDK4 CDKN2A RB1
5	PI3K-Akt signaling pathway ³⁷ Show member pathways Human papillomavirus infection ³⁷	12.82	CDK4 MDM2 RB1 TP53
6	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.75	CDK4 CDKN2A MDM2 RB1 TP53
7	Pathways in cancer ³⁷	12.72	CDK4 CDKN2A MDM2 RB1 TP53
8	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.64	CDK4 CDKN2A RB1 TP53
9	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.63	CDK4 CDKN2A MDM2 RB1 TP53
10	Chks in Checkpoint Regulation ⁶⁴ Show member pathways DNA Repair Mechanisms ⁶⁴ Estrogen-mediated S-Phase Entry ⁶⁴ G2-M Phase Transition ⁶⁴ Parkinson's Disease Pathway ⁶⁴ SREBP Proteolysis ⁶⁴	12.58	CDK4 MDM2 RB1 TP53
11	Mitotic G1-G1/S phases ⁶⁶ Show member pathways G1 to S cell cycle control ¹ G1/S Transition ⁶⁶	12.44	CDK4 CDKN2A MDM2 RB1 TP53
12	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ¹	12.43	MDM2 MUC1 RB1 TP53
13	MicroRNAs in cancer ³⁷	12.42	CDKN2A HMGA2 MDM2 TP53
14	DNA Damage ⁴	12.36	CDK4 CDKN2A MDM2 RB1 TP53
15	HTLV-I infection ³⁷	12.34	CDK4 CDKN2A RB1 TP53
16	Arrhythmogenic right ventricular cardiomyopathy (ARVC) ³⁷ Show member pathways Arrhythmogenic Right Ventricular Cardiomyopathy ¹ Calpain Protease Regulates Cellular Mechanics ⁶⁴	12.29	CDK4 DES RB1
17	Cyclins and Cell Cycle Regulation ⁶⁴ Show member pathways Cell Cycle Control by BTG Proteins ⁶⁴ Cyclin D associated events in G1 ⁶⁶ G1 Phase ⁶⁶ G1-S Phase Transition ⁶⁴ Phosphorylation of proteins involved in G1/S transition by active Cyclin E-Cdk2 complexes ⁶⁶	12.27	CDK4 CDKN2A RB1 TP53
18	DNA Damage Response ¹ Show member pathways miRNA Regulation of DNA Damage Response ¹ p53 signaling pathway ³⁷	12.22	CDK4 CDKN2A MDM2 RB1 TP53
19	DNA Damage/Telomere Stress Induced Senescence ⁶⁶ Show member pathways Formation of Senescence-Associated Heterochromatin Foci (SAHF) ⁶⁶ Packaging Of Telomere Ends ⁶⁶ Signal transduction Activin A signaling regulation ²²	12.21	HMGA2 RB1 TP53
20	Cell cycle ¹ ³⁷	12.19	CDK4 CDKN2A MDM2 RB1 TP53
21	Epstein-Barr virus infection ³⁷	12.16	MDM2 RB1 TP53
22	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.16	CDK4 MDM2 RB1 TP53
23	Transcriptional misregulation in cancer ³⁷	12.12	HMGA2 MDM2 TP53
24	Viral carcinogenesis ³⁷	12.11	CDK4 CDKN2A MDM2 RB1 TP53
25	Cell cycle Role of SCF complex in cell cycle regulation ²² Show member pathways Cell cycle ESR1 regulation of G1/S transition ²² Cell cycle Regulation of G1/S transition (part 1) ²² Immune response MIF-JAB1 signaling ²²	12.1	CDK4 CDKN2A RB1
26	Integrated Breast Cancer Pathway ¹	12.05	CDK4 MDM2 RB1 TP53
27	AKT Signaling Pathway ⁶⁷	12.02	CDK4 MDM2 TP53
28	Direct p53 effectors ¹	11.96	MDM2 RB1 TP53
29	SMAD Signaling Network ⁶⁴	11.96	CDKN2A MDM2 RB1 TP53
30	Cellular senescence (KEGG) ³⁷	11.92	CDK4 CDKN2A MDM2 RB1 TP53
31	Spinal Cord Injury ¹	11.91	CDK4 RB1 TP53
32	DNA Damage Response (only ATM dependent) ¹	11.89	CDKN2A MDM2 TP53
33	Senescence and Autophagy in Cancer ¹	11.84	CDKN2A MDM2 RB1 TP53
34	Small cell lung cancer ³⁷	11.8	CDK4 RB1 TP53
35	Retinoblastoma (RB) in Cancer ¹	11.72	CDK4 MDM2 RB1 TP53
36	Platinum drug resistance ³⁷	11.68	CDKN2A MDM2 TP53
37	Regulation of TP53 Expression and Degradation ⁶⁶ Show member pathways Regulation of TP53 Degradation ⁶⁶ Regulation of TP53 Expression ⁶⁶	11.67	CDKN2A MDM2 TP53
38	Glioblastoma Multiforme ⁶⁴	11.6	CDK4 CDKN2A MDM2 RB1 TP53
39	HIF1Alpha Pathway ⁶⁴	11.53	CDKN2A MDM2 TP53
40	Photodynamic therapy-induced AP-1 survival signaling. ¹	11.49	CDKN2A RB1 TP53
41	DNA damage_ATM/ATR regulation of G1/S checkpoint ²²	11.41	CDK4 MDM2 TP53
42	Integrated Cancer Pathway ¹	11.33	CDK4 MDM2 RB1 TP53
43	FOXM1 transcription factor network ¹	11.27	CDK4 RB1
44	GADD45 Pathway ⁶⁴	11.2	CDK4 TP53
45	Aurora A signaling ¹	11.18	MDM2 TP53
46	Oncogene Induced Senescence ⁶⁶	11.06	CDK4 CDKN2A MDM2 TP53
47	TP53 Network ¹ Show member pathways Activation, translocation and oligomerization of BAX ⁶⁶	11.05	CDKN2A MDM2 TP53
48	Bladder cancer ³⁷ ¹	10.88	CDK4 CDKN2A MDM2 RB1 TP53
49	Inhibition of Ribosome Biogenesis by p14(ARF) ⁶⁴	10.6	CDKN2A MDM2 RB1 TP53

Sources

GO Terms for Dedifferentiated Liposarcoma

Cellular components related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	chromatin	GO:0000785	9.13	CDK4 HMGA2 RB1
2	senescence-associated heterochromatin focus	GO:0035985	8.62	CDKN2A HMGA2

Biological processes related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

(show all 25)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription, DNA-templated	GO:0045893	9.89	CDKN2A HMGA2 RB1 TP53
2	negative regulation of apoptotic process	GO:0043066	9.88	ACTC1 HMGA2 MDM2 TP53
3	positive regulation of apoptotic process	GO:0043065	9.78	CDK4 CDKN2A HMGA2 TP53
4	cell cycle	GO:0007049	9.77	CDK4 CDKN2A HMGA2 RB1 TP53
5	cell cycle arrest	GO:0007050	9.72	CDKN2A RB1 TP53
6	G1/S transition of mitotic cell cycle	GO:0000082	9.67	CDK4 CDKN2A RB1
7	negative regulation of transcription, DNA-templated	GO:0045892	9.65	CDKN2A HMGA2 MDM2 RB1 TP53
8	base-excision repair	GO:0006284	9.62	HMGA2 TP53
9	muscle filament sliding	GO:0030049	9.62	ACTC1 DES
10	response to antibiotic	GO:0046677	9.61	MDM2 TP53
11	positive regulation of cell cycle arrest	GO:0071158	9.61	HMGA2 TP53
12	cellular response to gamma radiation	GO:0071480	9.6	MDM2 TP53
13	negative regulation of cell cycle arrest	GO:0071157	9.58	CDK4 MDM2
14	Ras protein signal transduction	GO:0007265	9.58	CDKN2A RB1 TP53
15	positive regulation of protein export from nucleus	GO:0046827	9.57	MDM2 TP53
16	positive regulation of cellular senescence	GO:2000774	9.56	CDKN2A HMGA2
17	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	GO:0006978	9.54	MUC1 TP53
18	positive regulation of transcription regulatory region DNA binding	GO:2000679	9.52	HMGA2 RB1
19	replicative senescence	GO:0090399	9.51	CDKN2A TP53
20	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	GO:0006977	9.5	MDM2 MUC1 TP53
21	amyloid fibril formation	GO:1990000	9.46	CDKN2A MDM2
22	negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle	GO:0031658	9.43	CDK4 CDKN2A
23	cellular response to actinomycin D	GO:0072717	9.16	MDM2 TP53
24	positive regulation of gene expression	GO:0010628	9.02	ACTC1 CDKN2A HMGA2 MDM2 TP53
25	senescence-associated heterochromatin focus assembly	GO:0035986	8.96	CDKN2A HMGA2

Molecular functions related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	enzyme binding	GO:0019899	9.56	HMGA2 MDM2 RB1 TP53
2	transcription factor binding	GO:0008134	9.46	CDKN2A HMGA2 RB1 TP53
3	SUMO transferase activity	GO:0019789	9.32	CDKN2A MDM2
4	p53 binding	GO:0002039	9.13	MDM2 MUC1 TP53
5	disordered domain specific binding	GO:0097718	8.92	CDKN2A MDM2 RB1 TP53

Sources

Sources for Dedifferentiated Liposarcoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia